ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 157.7 DKK -2.23%
Market Cap: 34.9B DKK
Have any thoughts about
ALK-Abello A/S?
Write Note

P/E
Price to Earnings

44.5
Current
59.4
Median
21.8
Industry
Lower than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
44.5
=
Market Cap
34.8B DKK
/
Net Income
785m DKK
All Countries
Close
Market Cap P/E
DK
ALK-Abello A/S
CSE:ALK B
34.8B DKK 44.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 87.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.9T DKK 30.1
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 23.7
US
Merck & Co Inc
NYSE:MRK
248.3B USD 20.4
CH
Roche Holding AG
SIX:ROG
197B CHF 17.1
UK
AstraZeneca PLC
LSE:AZN
160.1B GBP 31.3
CH
Novartis AG
SIX:NOVN
169.8B CHF 10.8
US
Pfizer Inc
NYSE:PFE
149.4B USD 35.1
Earnings Growth P/E to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 33.4
44.5
180%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
30.1
86%
0.4
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.1
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.3
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
42
2-Years Forward
P/E
29.8
3-Years Forward
P/E
25.6

See Also

Discover More